Levosulpiride, sold under the brand names Dislep and Sulpepta among others, is a dopamine antagonist medication which is used in the treatment of psychotic disorders like schizophrenia, major depressive disorder, nausea and vomiting, and gastroparesis. It is taken by mouth.

It is a selective antagonist of the dopamine D₂ receptor and an agonist of the serotonin 5-HT₄ receptor. Chemically, it is a benzamide and the (S)-(−)-enantiomer of sulpiride.

Levosulpiride is marketed widely throughout the world, including in Europe, South Korea, Latin America, India, and Pakistan. It is not available in the United States or the United Kingdom.

Levosulpiride is used in the treatment of:

Levosulpiride is not currently licensed for treatment of premature ejaculation in the United Kingdom or other European countries.

Side effects of levosulpiride include amenorrhea, gynecomastia, galactorrhea, changes in libido, and neuroleptic malignant syndrome. In the United States, as of 2013 only one case of adverse reaction to levosulpiride had been recorded on the FDA Adverse Event Reporting System Database. A case of rapid-onset resistant dystonia caused by low-dose levosulpiride was reported in India.

Levosulpiride is a selective dopamine D₂ receptor antagonist. The drug has also been found to act as a moderate agonist of the serotonin 5-HT₄ receptor. It is said to have antipsychotic, antidepressant, antiemetic, and gastroprokinetic effects.

Levosulpiride is a substituted benzamide derivative. It is the levorotatory enantiomer of sulpiride. Other benzamide derivatives include amisulpride, metoclopramide, tiapride, sultopride, and veralipride, among others.